La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Swedish Orphan Biovitrum Gestion

Gestion contrôle des critères 3/4

Le PDG Swedish Orphan Biovitrum's est Guido Oelkers, nommé en May2017, a un mandat de 7.25 ans. La rémunération annuelle totale est SEK 48.88M, composée du salaire de 25.1% et des bonus 74.9%, y compris les actions et options de la société. détient directement 0.12% des actions de la société, d'une valeur de SEK 133.17M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.6 ans et 3.8 ans.

Informations clés

Guido Oelkers

Directeur général

SEK 48.9m

Rémunération totale

Pourcentage du salaire du PDG	25.1%
Durée du mandat du directeur général	7.3yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Recent updates

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Mar 28

Analyse de la rémunération des PDG

Comment la rémunération de Guido Oelkers a-t-elle évolué par rapport aux bénéfices de Swedish Orphan Biovitrum?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

Rémunération vs marché: La rémunération totale de Guido ($USD 4.74M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 2.83M ).

Rémunération et revenus: La rémunération de Guido a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Guido Oelkers (59 yo)

7.3yrs

Titularisation

SEK 48,883,000

Compensation

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Guido Oelkers	CEO & President	7.3yrs	SEK 48.88m	0.12% SEK 139.3m
Henrik Stenqvist	Chief Financial Officer	6.2yrs	pas de données	0.016% SEK 18.4m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.7yrs	pas de données	0.0089% SEK 9.9m
Daniel Rankin	Head of Strategy & Corporate Development	2.7yrs	pas de données	0.0029% SEK 3.2m
Lena Bjurner	Head of Human Resources	1.7yrs	pas de données	pas de données
Armin Reininger	Senior Scientific & Medical Advisor	7.7yrs	pas de données	0.0046% SEK 5.2m
Norbert Oppitz	Head of International	6.9yrs	pas de données	0.012% SEK 13.0m
Sofiane Fahmy	Head of Europe	5.7yrs	pas de données	0.0077% SEK 8.7m
Duane Barnes	Head of North America	3.7yrs	pas de données	pas de données
Mahmood Ladha	Head of Strategic Transformation Operations	no data	pas de données	0.0018% SEK 2.0m
Christine Wesstrom	Head of Technical Operations	2.5yrs	pas de données	0.0032% SEK 3.6m
Lydia Abad-Franch	Senior VP	1.7yrs	pas de données	pas de données

5.7yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de SOBI est chevronnée et expérimentée (ancienneté moyenne 5.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Hans Wigzell	Chairman of Scientific Advisory Board	23.7yrs	SEK 158.00k	pas de données
Helena Saxon	Director	13.4yrs	SEK 828.00k	0.0066% SEK 7.5m
Anders Ullman	Director	1.3yrs	SEK 463.00k	0.0010% SEK 1.1m
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	pas de données	pas de données
Ralf Pettersson	Member of Scientific Advisory Board	no data	pas de données	pas de données
Stefan Del Prato	Member of Scientific Advisory Board	no data	pas de données	pas de données
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	pas de données	pas de données
Annette Clancy	Independent Chairman	10.3yrs	SEK 770.00k	0.00099% SEK 1.1m
Staffan Schuberg	Independent Director	4.3yrs	SEK 827.00k	0.0021% SEK 2.3m
Filippa Stenberg	Director	3.3yrs	SEK 673.00k	0.00017% SEK 190.9k
Katy Mazibuko	Employee Representative Director	1.7yrs	pas de données	0.0013% SEK 1.4m
Christophe Bourdon	Independent Director	1.3yrs	SEK 433.00k	pas de données

3.8yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de SOBI sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

Swedish Orphan Biovitrum Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

CEO & President recently sold kr29m worth of stock

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Recent updates

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

Investor sentiment improves as stock rises 15%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold kr29m worth of stock

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations